Welcome to our dedicated page for BSTC news (Ticker: BSTC), a resource for investors and traders seeking the latest updates and insights on BSTC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BSTC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BSTC's position in the market.
BioSpecifics Technologies Corp. (NASDAQ: BSTC) has completed its acquisition by Endo International plc (NASDAQ: ENDP) for approximately $658.2 million. The all-cash tender offer for BioSpecifics' shares was priced at $88.50 per share, with approximately 6.16 million shares tendered, representing 82.8% of outstanding shares. The acquisition was executed through a merger, and BioSpecifics will be delisted from Nasdaq. The companies aim to leverage BioSpecifics' collagenase product, XIAFLEX®, and expand Endo's offerings, including its new cellulite treatment, Qwo™.
Endo International announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its tender offer to acquire BioSpecifics Technologies Corp. The offer price is set at $88.50 per share, with the transaction expected to close in early December 2020, pending remaining conditions. The Boards of Directors of both companies have approved the Merger Agreement, and BioSpecifics' Board recommends that its stockholders tender their shares. The offer is scheduled to expire on December 1, 2020.
BioSpecifics Technologies Corp. (NASDAQ: BSTC) reported its third-quarter financial results for 2020, showing a net income of $5.4 million, down from $6.3 million in 2019. Total revenue was $11.3 million, a 2% decrease year-over-year, but a strong 137% recovery from the prior quarter due to improved conditions after COVID-19 disruptions. The company has cash reserves of $121.0 million as of September 30, 2020, and announced its acquisition by Endo International, with a valuation of approximately $658 million expected to close in Q4 2020.
Endo International plc announced its tender offer to acquire all outstanding shares of BioSpecifics Technologies Corp. at $88.50 per share. The tender offer commenced on November 2, 2020, under a Merger Agreement dated October 19, 2020. The board of directors of BioSpecifics recommends stockholders tender their shares, stating the transaction is fair and in their best interests. The offer is set to expire at 11:59 PM on December 1, 2020. Further details will be filed with the SEC.
BioSpecifics Technologies Corp. (NASDAQ: BSTC) has entered a definitive merger agreement for Endo International plc (NASDAQ: ENDP) to acquire BioSpecifics for approximately $658 million in equity value, translating to $88.50 per share. Both boards unanimously approved the transaction, expected to close in Q4 2020. Endo will launch an all-cash tender offer for all outstanding BioSpecifics shares, subject to conditions including majority share tendering and antitrust approvals. This acquisition builds on the existing collaboration between the companies in collagenase-based therapies.
Endo International plc (NASDAQ: ENDP) has announced an agreement to acquire BioSpecifics Technologies Corp. (NASDAQ: BSTC) for $88.50 per share, valuing the deal at approximately $540 million. This acquisition is set to enhance Endo's portfolio, particularly its collagenase-based therapies, including XIAFLEX and Qwo, which are positioned for long-term growth. The transaction is expected to close in late 2020 and has been unanimously approved by both companies' boards. Endo plans to fund the acquisition using cash on hand.
BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced that CEO Joseph Truitt will present at the virtual Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 21, 2020, at 4:10 p.m. ET. A live webcast will be available on the company’s website, with an archived replay accessible for 90 days. BioSpecifics specializes in collagenase-based therapies, including XIAFLEX®, used for treating Dupuytren's contracture and Peyronie's disease. The company is also expanding its pipeline, expecting Qwo™ to launch in early 2021 for cellulite treatment.
BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced that CEO Joseph Truitt will present at the H.C. Wainwright Virtual Healthcare Conference on September 14, 2020, at 3:00 p.m. ET. The live webcast can be accessed on the BioSpecifics website, with an archived replay available for 90 days post-event. BioSpecifics develops collagenase-based therapies, including XIAFLEX, for conditions like Dupuytren's contracture. Recent FDA approval of CCH for moderate to severe cellulite will expand the product range, with Qwo™ expected to launch in the U.S. in H1 2021.
BioSpecifics Technologies Corp. (NASDAQ: BSTC) reported a significant decline in financial performance for Q2 2020, with total revenue of $3.9 million, a 56% drop year-over-year, mainly due to COVID-19 impacts. GAAP net income fell to $0.1 million ($0.02 per share) compared to $6.4 million ($0.88 per share) in Q2 2019. Despite these challenges, the company maintains a strong cash position of $119.8 million and anticipates a rebound in XIAFLEX® royalties in the latter half of 2020. New FDA approvals and clinical trials for its products are also underway.
BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced the appointment of Alex Monteith as Senior Vice President and Chief Business Officer. Monteith brings extensive experience in business development, previously serving at Deerfield Management and Achillion Pharmaceuticals. His appointment aims to enhance the execution of the company's strategy, focusing on new XIAFLEX indications and expanding the portfolio. The company is also preparing for the commercial launch of Qwo™ in 2021, following FDA approval for cellulite treatment.
